Syndax Pharmaceuticals Inc. (SNDX)
NASDAQ: SNDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SNDX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $785.05M
- EPS (TTM)
- -$2.37
- Dividend yield
- None
- 52-week range
- 8.41 – 25.59
- Day range
- 8.69 – 9.27
- Volume / Avg
- 2.18M / 2.63M
- Beta
- —
- Shares outstanding
- 90.03M
52-week range
SNDX stock today
On Nov 20, SNDX ended the session at $8.72, shedding $0.41 (4.49%), versus the S&P 500's 3.70% decline. Shares are 65.9% below their 52-week high of $25.59, set on Mar 25, 2026 and 3.7% above the 52-week low of $8.41, near the bottom of the past year's range. SNDX is down 58.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 50.0%.
Syndax Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.37), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Syndax Pharmaceuticals
Company profileSyndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Michael A. Metzger M.B.A.
- Headquarters
- New York, NY
- Employees
- 298
- IPO year
- 2016
- Website
- syndax.com
Financial highlights
Full financialsIn fiscal 2025, Syndax Pharmaceuticals generated $172.4 million in revenue, up 627.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Syndax Pharmaceuticals reported a net loss of $285.4 million, compared with a loss of $318.8 million a year earlier. Operating margin was -158.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $172.35M | $23.68M | $0 | $0 | $139.71M |
| Growth | +627.84% | — | — | -100.00% | +9109.56% |
| Net income | $-285.42M | $-318.76M | $-209.36M | $-149.34M | $24.93M |
| EPS (diluted) | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.46 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$35.45+306.54%
- Strong buy 2
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 2, 2026
- EPS actual vs est.
- $-0.55 vs $-0.52
- Surprise
- -5.77%
SNDX news
All SNDX news- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXPR Newswire
- Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXPR Newswire
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026GlobeNewswire
- Syndax Posts Q3 Loss Narrows As Revenue Jumps 82% On Revuforj, Niktimvo GrowthNasdaqINCY, SNDX, SUN
- Syndax (SNDX) Q3 2026 Earnings Call TranscriptNasdaq
- Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial OfficerGlobeNewswire
Syndax Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IRWDIronwood Pharmaceuticals Inc. Class A | 4.70 | -0.21% | $778.09M | vs SNDX |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs SNDX |
| COLLCollegium Pharmaceutical Inc. | 24.72 | -1.94% | $768.18M | vs SNDX |
| ORICOric Pharmaceuticals Inc. | 7.36 | -4.42% | $764.94M | vs SNDX |
| RIGLRigel Pharmaceuticals Inc. | 40.09 | -2.67% | $754.89M | vs SNDX |
| CRVSCorvus Pharmaceuticals Inc. | 9.67 | -3.40% | $815.69M | vs SNDX |
| PHARPharming Group N.V. ADS | 11.54 | -5.10% | $816.78M | vs SNDX |
| ARDXArdelyx Inc. | 2.99 | -2.29% | $751.60M | vs SNDX |
Indexes, lists and sector
Syndax Pharmaceuticals stock FAQ
What is Syndax Pharmaceuticals's stock price today?
SNDX last traded at $8.72 as of Nov 20, 4:00 PM EST, down 4.49% on the day. Prices are delayed at least 15 minutes.
Who is Syndax Pharmaceuticals's CEO?
Mr. Michael A. Metzger M.B.A. is the chief executive officer of Syndax Pharmaceuticals Inc., which has about 298 employees.
What is the SNDX 52-week high?
The 52-week high for SNDX is $25.59 and the 52-week low is $8.41. The stock is currently 65.9% below its high.